Dr. Lori J. Maness-Harris, MD

Dr. Maness-Harris practices at Nebraska Medical Center in Omaha, Nebraska, part of University of Nebraska System.

Dr. Maness-Harris' NPI, 1548219553, was assigned on May 8, 2006. Dr. Maness-Harris graduated from State University of NY Upstate Medical University in 1997. Dr. Maness-Harris holds Nebraska license 22579.

Dr. Maness-Harris' primary practice is Nebraska Medical Center, at 988102 Nebrasks Medical Center, Omaha, NE 68198 in Douglas County. The practice phone is (402) 559-4000. Dr. Maness-Harris also practices at Nebraska Medical Center, 987400 Nebraska Medical Ctr, Omaha, NE 68198.

Dr. Maness-Harris' primary practice is Nebraska Medical Center in Omaha, Nebraska, part of University of Nebraska System. Dr. Maness-Harris is also affiliated with Bellevue Medical Center. The medical group on file is UNMC Physicians. Dmand AI also links Dr. Maness-Harris to 2 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Maness-Harris practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Maness-Harris' primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Maness-Harris is licensed in Nebraska.

CMS data shows 782 Medicare services from Dr. Maness-Harris across 7 procedure codes in 2024, for 216 Medicare patients. Medicare paid $50,974 for them.

CMS counts 216 Medicare patients who saw Dr. Maness-Harris in 2024. The largest group is 65 to 74, with 110 patients. 72% of them have high blood pressure, and 70% have high cholesterol. 5% are also on Medicaid. Their average risk score is 2.97, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Maness-Harris' median patient age at 73, with 50% women.

In 2024, Dr. Maness-Harris wrote 1,666 Medicare Part D claims for 130 patients. 62% of them were for generic drugs. CMS names the drug for 1,370 of them, across 42 drugs with 11 or more claims each, at $5,222,060 in total drug cost. In 2023, CMS named 1,297 claims across 39 drugs.

Dr. Maness-Harris accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Maness-Harris as offering telehealth.

Dmand AI links 4 papers to Dr. Maness-Harris, published from 2022 to 2024. The most frequent topics are Hematopoietic Stem Cell Transplantation. Dr. Maness-Harris' most frequent co-authors are Vijaya Raj Bhatt, MD, Krishna Gundabolu, MD and Yasmin Abaza, MD.

Dmand AI links Dr. Maness-Harris to 3 clinical trials. 1 is still active or recruiting. Conditions studied include Leukemia, Myeloid, Acute, Leukemia, Myeloid, Chronic-Phase and Myelodysplastic Syndromes. National Cancer Institute (NCI) sponsors the most, 2.

CMS Open Payments shows 2 general payments to Dr. Maness-Harris from 2 drug and device companies from 2016 to 2024. Food and beverage make up the largest share, 100% of the total. Celgene Corporation paid the most, $29.

Dr. Maness-Harris graduated from State University of NY Upstate Medical University in 1997.